Light AI Inc.
0.04
EUR
+0.00
(-4.55%)
ISIN
CA53229R1047
CUSIP
53229R104
Return %
Stock
S&P 500
1Y
-59.02
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Vancouver Canada
- Website
- light.ai
- Similar Companies
- Business
- Light AI Inc. is a digital healthcare technology company that specializes in artificial intelligence-driven diagnostic and clinical decision-support solutions. Headquartered in Vancouver, British Columbia, Canada, the company operates in the software as a medical device sector, developing computer vision and machine learning technologies that transform standard smartphone photography into rapid, point-of-care diagnostic tools for infectious diseases and clinical screening. The company offers its proprietary software products and clinical applications, which include: Light AI QuickScan Strep A, a Health Canada-licensed Class II Software as a Medical Device application that applies proprietary artificial intelligence algorithms to digital throat images for the rapid point-of-care detection and triage of Group A streptococcal infections; Light AI Diagnostic Engine, a device-agnostic artificial intelligence platform providing image analysis, mucosal tissue assessment, and real-time clinical decision-support integration; and the QuickScan Diagnostic Pipeline, an expanding suite of software algorithms engineered to support upper respiratory screening, dermatological triage, and automated clinical evaluation workflows for telemedicine networks, primary care clinics, ambulatory centers, and remote health practitioners across North America and international markets. In recent corporate developments, the company completed a three-cornered statutory amalgamation and reverse takeover involving Mojave Brands Inc. in December 2024 to become Light AI Inc., subsequently listing its common shares on Cboe Canada under the ticker ALGO in January 2025. In August 2026, Light AI secured a Class II Medical Device License from Health Canada for its QuickScan Strep A application to initiate commercialization in Canada. In June 2026, the company commenced an FDA pivotal clinical trial in the United States to support domestic regulatory clearance and initiated an international field validation study in New Zealand in collaboration with the National Hauora Coalition. Operationally, the company expanded its executive leadership team in 2026 by appointing John R. Luna as Chief Executive Officer and Mark Orsmond as Chief Financial Officer, while founder Peter Whitehead transitioned to Chief Innovation Officer.